| name | Doripenem |
| classification | Carbapenem antibiotic |
| pharmacokinetics | | absorption | Well absorbed after intravenous administration. Bioavailability is high. | | distribution | Distributes widely throughout the body, including the cerebrospinal fluid (CSF) with penetration into many tissues and organs. Exhibits good penetration into the bone. | | metabolism | Metabolized primarily by the kidneys, with minimal hepatic metabolism. | | excretion | Eliminated primarily by renal excretion. The drug is primarily excreted unchanged in the urine. |
|
| suggested dosage | | adult | Typically administered intravenously as a 500 mg dose every 8 hours. Adjustments may be needed based on renal function and specific infection. | | note | Dosage should be carefully calculated based on the patient's creatinine clearance. Consult prescribing information and local guidelines for precise dosage. |
|
| indications | | 1 | Treatment of complicated intra-abdominal infections | | 2 | Treatment of complicated urinary tract infections | | 3 | Treatment of hospital-acquired pneumonia | | 4 | Treatment of other serious infections caused by susceptible organisms |
|
| safety pregnancy | | classification | Category B. Animal studies have not demonstrated fetal risk, but adequate and well-controlled studies in pregnant women are lacking. | | note | Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Monitor the mother and fetus closely. |
|
| safety breastfeeding | | classification | Data are limited regarding excretion into breast milk. Use with caution during breastfeeding. Assess the potential benefit to the mother against the potential risk to the infant. | | note | Discontinuation of breastfeeding or doripenem may be necessary depending on the clinical situation. |
|
| side effects | | 1 | Nausea | | 2 | Vomiting | | 3 | Diarrhea | | 4 | Headache | | 5 | Phlebitis (at the IV site) | | 6 | Elevated liver enzymes | | 7 | Superinfection (e.g., C. difficile-associated diarrhea) | | 8 | Hypersensitivity reactions (e.g., rash, urticaria, anaphylaxis) | | 9 | Clostridium difficile-associated diarrhea is a serious potential side effect, especially with prolonged use. |
|
| alternatives | |
| contraindications | | 1 | Hypersensitivity to doripenem or other carbapenem antibiotics | | 2 | Known history of severe hypersensitivity reactions (e.g., anaphylaxis) to other drugs. |
|
| interactions | | 1 | May potentiate the effects of nephrotoxic drugs. Monitor kidney function when given with such drugs. | | 2 | May increase the risk of nephrotoxicity when used in combination with aminoglycosides. |
|
| warnings precautions | | 1 | Monitor renal function closely, particularly in patients with pre-existing renal impairment. | | 2 | Use with caution in patients with a history of seizures or conditions that might lower the seizure threshold. | | 3 | Observe for signs of allergic reactions (rash, hives, difficulty breathing) and discontinue the medication if they appear. |
|
| additional information | | important notes | | 1 | Doripenem should be administered by intravenous infusion, not intramuscularly or orally. | | 2 | Ensure appropriate infection control measures are followed for administration. |
|
|
